StreetSmart Live! Presents FansUnite Entertainment Inc on 11/30/2020. Learn More

Streetwise Biotech / Pharmaceuticals Articles

Pharma Developer Raises Enrollment Goal for Multinational Phase 2b/3 COVID-19 Trial
Source: Streetwise Reports  (11/25/20)
Algernon Pharmaceuticals reported it has enrolled 154 patients in its Phase 2b/3 human study of Ifenprodil for COVID-19 and is increasing the pool to 168 patients to allow for attrition. More >

Biopharma Targeting Glioblastoma Multiforme Commences Clinical Program
Source: Streetwise Reports  (11/25/20)
Preclinical results for Black Diamond Therapeutics' kinase inhibitor, BDTX-1535, are reviewed in an H.C. Wainwright & Co. report. More >

U.S. Biopharma Expands Into ALS, Doses First Patient in 'Potentially Pivotal' Trial
Source: Streetwise Reports  (11/25/20)
The design of Apellis Pharmaceuticals and its partner's clinical study is presented in a ROTH Capital Partners report. More >

Renalytix AI Shares Climb 30% on Q1 Earnings and EUA for JV's SARS-CoV-2 IgG Antibody Test Kit
Source: Streetwise Reports  (11/25/20)
Shares of Renalytix AI Plc. traded 30% higher after the company reported Q1/21 financial results and that its joint venture with Mt. Sinai Health System was granted Emergency Use Authorization by the FDA for its SARS-CoV-2 IgG antibody test kit. More >

Biotech Collaborates to Advance Psychedelics Use in Cancer, Other Applications
Source: Streetwise Reports  (11/23/20)
Revive Therapeutics enters an agreement with PharmaTher, a specialty psychedelics pharmaceutical firm. More >

Precision BioSciences & Eli Lilly Partner to Develop In Vivo Therapies for Genetic Disorders
Source: Streetwise Reports  (11/20/20)
Precision BioSciences shares traded 13% higher after the company reported it is partnering with Eli Lilly & Co. to develop in vivo therapies for genetic disorders with an initial focus on Duchenne's muscular dystrophy and two other undisclosed gene targets. More >

Corcept Therapeutics Shares Rise 25% on Favorable U.S. Patent Office Ruling
Source: Streetwise Reports  (11/19/20)
Shares of Corcept Therapeutics reached a new 52-week high after the firm reported that the U.S. Patent Trial and Appeals Board affirmed that all claims pertaining to its U.S. Patent No.10,195,214 are valid. More >

Kodiak Sciences Announces Pricing of $560.9 Million Common Stock Offering
Source: Streetwise Reports  (11/18/20)
Kodiak Sciences shares reached a new 52-week high after the company announced the pricing of a $560.9 million public offering of its common stock. The report came one day after the firm advised it had completed enrollment of its Phase 2b/3 Pivotal DAZZLE Study of KSI-301 in patients with wet age-related macular degeneration. More >

Lexicon Shares Rise 40% upon Achieving Primary Endpoints in Two Phase 3 Heart Failure Studies
Source: Streetwise Reports  (11/17/20)
Shares of Lexicon Pharmaceuticals traded higher after the company published results from the Phase 3 SOLOIST and SCORED trials showing that sotagliflozin significantly reduced total cardiovascular deaths, heart failure hospitalization and urgent visits. More >

Psychedelic Company Expected to Begin Trading Nov. 18
Source: Streetwise Reports  (11/17/20)
Delic Corp., a thought leader in psychedelics, will trade on the Canadian Securities Exchange. More >

Moderna Shares Get a Boost from Phase 3 COVID-19 Vaccine Trial Data Demonstrating 94.5% Efficacy
Source: Streetwise Reports  (11/16/20)
Moderna shares traded 10% higher to a new 52-week high after the company reported its COVID-19 vaccine candidate, mRNA-1273, met its primary endpoint in the first interim analysis of the Phase 3 COVE Study by achieving an efficacy rate of 94.5%. More >

Life Sciences Firm Completes Development of Dissolvable Oral Psilocybin
Source: Streetwise Reports  (11/14/20)
Revive Therapeutics reported that it has developed an oral thin-film strip psilocybin product with doses ranging from 1 to 20 milligrams. More >

Urovant Sciences Shares Double on Sumitovant Biopharma Buyout Offer
Source: Streetwise Reports  (11/13/20)
Shares of Urovant Sciences traded 93% higher to a new 52-week high after the company reported that it entered into a definitive agreement to be acquired by Sumitovant Biopharma for $16.25 per share in cash. More >

Biotech Involved in COVID-19, Neurodegenerative Diseases Reports Q3/20 Results
Source: Streetwise Reports  (11/12/20)
ProMIS Neurosciences formed two new joint ventures, one for developing tests for the detection, diagnosis and monitoring of Alzheimer's disease, and the second for serological assays for antibodies to the SARS-CoV-2 virus. More >

Biotech Comments on FDA Advisory Committee Recommendation of Not Licensing Alzheimer's Drug
Source: Streetwise Reports  (11/11/20)
ProMIS Neurosciences, which is developing its own therapeutics for this disease, weighs in on the committee's conclusions regarding Biogen's aducanumab. More >

Biotech Plans to Release Interim Data for Phase 2b/3 COVID-19 Trial in December
Source: Streetwise Reports  (11/11/20)
Algernon Pharmaceuticals reported it intends to announce the interim results from its Ifenprodil Phase 2b/3 COVID-19 human study during the first week of December 2020. More >

Biopharma Posts 'Impressive' Q3/20 Sales Amid Pandemic
Source: Streetwise Reports  (11/11/20)
Paratek Pharmaceuticals' recent and future revenue are discussed in an H.C. Wainwright & Co. report. More >

Five Prime Shares Triple in Value as Firm Meets All 3 Primary Endpoints in Phase 2 Gastric and GEJ Cancer Trial
Source: Streetwise Reports  (11/11/20)
Five Prime Therapeutics shares traded 250% higher after the firm reported topline data from its Phase 2 FIGHT study of bemarituzumab in combination with chemotherapy demonstrated significant progression-free and overall survival rates in advanced gastric and gastroesophageal junction cancer. More >

Pfizer and BioNTech Announce Extremely Positive Phase 3 COVID-19 Vaccine Trial Data; Production of 1.3 Billion Doses in 2021 Planned
Source: Streetwise Reports  (11/9/20)
Pfizer shares traded 9% higher to a new 52-week high after the company reported that interim data from its Phase 3 COVID-19 vaccine trial with BioNTech showed a 90% success rate in participants without prior evidence of SARS-CoV-2 infection. The company is making plans to produce up to 1.3 billion vaccine doses in 2021. More >

Glaukos Shares Pressured Higher After Firm Reports 11% Rise in Q3 Revenue
Source: Streetwise Reports  (11/6/20)
Shares of Glaukos Corp. traded 9% higher after the company reported Q3/20 financial results that included an 11% YoY increase in glaucoma and corneal health net sales. More >

U.S. Biotech Developing Cancer Therapeutics Has 'Deep Pipeline'
Source: Streetwise Reports  (11/4/20)
ImmunoGen's broad pipeline that "could support long-term growth" is discussed in an H.C. Wainwright & Co. report. More >

Supernus Pharma Shares Trade Up 21% on 52% Increase in Q3 YoY Revenue
Source: Streetwise Reports  (11/4/20)
Shares of Supernus Pharmaceuticals traded higher after the company reported financial results for Q3/20 that included a 52% increase in total revenues versus the same period in 2019. More >

Multinational Phase 2b/3 COVID-19 Study Approved to Continue
Source: Streetwise Reports  (11/2/20)
Two doses of Algernon Pharmaceuticals' NP-120, or Ifenprodil, are being tested for safety and efficacy. More >

Biotech Expects Interim Analysis Data from Phase 3 COVID-19 Study by Year-End
Source: Streetwise Reports  (10/28/20)
Revive Therapeutics anticipates that more than 200 patients will complete its Phase 3 clinical trial of Bucillamine in patients with mild-moderate COVID-19 by the end of December 2020 and stated that those results will help identify the best dosage levels for the rest of the trial. More >

Mirati Therapeutics' Shares Rise 12.5% on Positive Data from Cancer Studies
Source: Streetwise Reports  (10/26/20)
Mirati Therapeutics' shares reached a new 52-week high after the company reported preliminary data for Adagrasib (MRTX849) demonstrated durable anti-tumor activity in its non-small cell lung cancer and colorectal cancer studies. More >

Showing Results: 1 to 25 of 1267 Next

Notable Quotes

"New targets keep popping up due to CBR's exploration at Cuiu Cuiu."
– Brien Lundin, Gold Newsletter (Jefferson Financial)
"SCOT is a bargain and Buy at current trading levels."
– Brien Lundin, Gold Newsletter (Jefferson Financial)

Get Our Streetwise Reports Newsletter Free and be the first to know!

A valid email address is required to subscribe